WebDoctor Encyclopedia

Liver, bile ducts & pancreas Lung Soft-tissue sarcomas

Epithelioid haemangioendothelioma (EHE)

Epithelioid haemangioendothelioma (EHE) is a very rare vascular sarcoma that grows in the liver, lungs, bone or soft tissue, often in several places at once. It is usually slow-growing and may be watched, removed or treated with sirolimus.

Medically reviewed Last reviewed October 17, 2026

What is epithelioid haemangioendothelioma?

Epithelioid haemangioendothelioma (EHE) is a very rare cancer that starts in the cells lining blood vessels (endothelial cells). It is a type of vascular sarcoma, a cancer of the body’s connective tissues.

EHE most often grows in the liver, the lungs, bone and soft tissues. In many people, it is found in more than one place at the time of diagnosis, most commonly in both the liver and the lungs.

EHE is unusual because its behaviour varies a lot from person to person. In some people it grows very slowly and may stay stable for many years without treatment. In others it behaves more aggressively and spreads (Stacchiotti et al., 2021).

The World Health Organization classifies EHE as a malignant tumour (Sbaraglia, Bellan and Dei Tos, 2021). It is so rare that it affects only around 1 person in a million each year, so care is best organised through specialist sarcoma centres.

1. Key facts at a glance

Feature Details
Type of cancer Rare vascular sarcoma of blood vessel lining cells
How common About 1 in a million people a year
Typical age Usually adults aged 30-50; can occur in children and older people
Main sites Liver, lungs, bone and soft tissue; often several at once
Key symptoms Often none; pain in the upper abdomen, chest pain, cough, tiredness
Gene changes WWTR1::CAMTA1 fusion in about 90%; YAP1::TFE3 in most of the rest
Main treatment Surgery, liver transplant, active surveillance, sirolimus and other drug treatments
Outlook Highly variable; many people live for years, but aggressive forms occur

2. Types of EHE

By site

Site Notes
Liver The most common site; usually many nodules in both halves of the liver
Lung Often many small nodules in both lungs; may cause fluid around the lungs
Bone Single or several bone lesions; may cause pain or fractures
Soft tissue A lump in a limb or the trunk, often linked with a blood vessel
Other sites Lymph nodes, skin, heart, brain coverings and others, rarely

By genetic type

Genetic type Notes
WWTR1::CAMTA1 (TAZ::CAMTA1) Found in about 90% of EHE; the classic form (Errani et al., 2011)
YAP1::TFE3 About 5-10%; often younger patients; looks slightly different under the microscope (Antonescu et al., 2013)
Other rare fusions Being studied

3. Causes and risk factors

The cause of EHE is not known. It develops when two genes break and join together inside a cell, creating a fusion gene. This fusion switches on growth programmes in the blood vessel cell.

The fusion gene arises by chance during a person’s life. It is not inherited and cannot be passed on to children.

Question Answer
Is EHE linked with lifestyle? No lifestyle cause has been found
Is it linked with alcohol or liver disease? No; liver EHE usually occurs in a healthy liver
Is it more common in women? Liver EHE is somewhat more common in women
Is it contagious? No

4. How does it look

On scans of the liver

Feature Description
Number Usually many nodules in both halves of the liver
Position Often near the surface of the liver
Growth pattern Nodules may join together into larger areas
Capsular retraction The liver surface may pull inwards over a nodule, a typical clue
Target appearance Rings of different density on CT or MRI
“Lollipop sign” A nodule with a blood vessel ending at its edge on scans

On scans of the lungs

The lungs usually show many small nodules on both sides. Some people have thickening of the lining of the lungs or a pleural effusion (fluid around the lungs), which is linked with a more aggressive course (Lau et al., 2011).

Bone and soft tissue

In bone, EHE often appears as areas of bone loss with clear edges, sometimes in several bones. In soft tissue it forms a firm lump, sometimes attached to a vein.

Under the microscope

Feature Description
Cell shape Rounded “epithelioid” cells with pink cytoplasm
Arrangement Cords and strands of cells in a pale, gel-like background
Vacuoles Small holes inside cells, sometimes containing red blood cells; a sign of early blood vessel formation
Markers Positive for CD31, CD34 and ERG, which are blood vessel markers
Fusion markers Nuclear CAMTA1 staining, or TFE3 staining in the YAP1::TFE3 type

Visible signs

Most people with EHE look well. Visible signs are uncommon, but a lump may be felt in soft-tissue EHE, and widespread liver disease can rarely cause yellowing of the skin (jaundice) or a swollen abdomen.

5. Symptoms

Many people have no symptoms, and EHE is found by chance on a scan done for another reason.

Liver EHE

  • Pain or discomfort under the ribs on the right side
  • Tiredness and weakness
  • Loss of appetite and weight loss
  • Swelling of the abdomen in advanced disease
  • Jaundice, rarely

Lung EHE

  • Cough, sometimes with blood
  • Chest pain, especially when breathing in
  • Breathlessness, particularly if fluid builds up around the lungs

Bone and soft-tissue EHE

  • Bone pain, often worse at night
  • A fracture after a minor injury
  • A lump that may be painful
  • Swelling of a limb if a vein is involved

General symptoms

Symptom Notes
Fatigue Common and can be severe
Fever and night sweats In some people
Weight loss More common in active disease
Pain Depends on site; may need specialist pain care

When to seek medical advice

See a doctor if you have ongoing abdominal pain, cough, chest pain or a new lump.

Seek prompt help for worsening breathlessness, coughing up blood or yellowing of the skin.

6. Diagnosis

Test Purpose
CT of the chest, abdomen and pelvis Shows the size and number of lesions
MRI of the liver Gives a detailed view of liver nodules
PET-CT Shows active areas and helps with staging
Biopsy Essential to confirm the diagnosis
Immunohistochemistry Confirms blood vessel markers and CAMTA1 or TFE3
Molecular testing Confirms the fusion gene
Blood tests Liver and kidney function and general health
Echocardiogram If fluid around the heart is suspected

Conditions that can look similar

Condition How it differs
Metastatic cancer Comes from a cancer elsewhere; different markers
Angiosarcoma A more aggressive vascular sarcoma without the EHE fusion
Epithelioid haemangioma A benign vascular tumour
Cholangiocarcinoma A bile duct cancer with different markers

7. Treatment

EHE should be managed by a specialist sarcoma team. An international expert consensus guides care (Stacchiotti et al., 2021).

Active surveillance

Because EHE can be stable for long periods, many people with disease in several organs but no symptoms are offered active surveillance. This means regular scans every few months, with treatment started only if the disease grows or causes symptoms.

Local treatments

Treatment When it is used
Surgery For EHE in one place or a few places that can be safely removed
Liver transplantation For selected people with liver-only disease that cannot be removed (Mehrabi et al., 2006)
Radiotherapy For bone or soft-tissue lesions, or to control pain
Ablation or embolisation Sometimes for liver nodules

Drug treatment

Drug Notes
Sirolimus An mTOR inhibitor and a common first-line drug for progressing disease; can stabilise EHE for long periods (Stacchiotti et al., 2023)
Chemotherapy Paclitaxel or anthracycline-based treatment, mainly for aggressive disease
Anti-angiogenic drugs Such as pazopanib, in some people
Trametinib and other targeted drugs Studied in clinical trials
Interferon Used in some centres in the past

Supportive care

Problem Help available
Pleural effusion Draining the fluid, sometimes a long-term drain
Pain Pain relief medicines and specialist pain teams
Fatigue Pacing, exercise, treatment of anaemia
Emotional strain Counselling and patient support groups

Liver transplantation in more detail

For people whose EHE is limited to the liver but cannot be removed with surgery, a liver transplant can offer long-term control. Results are much better than for most other cancers treated in this way, and many people remain well for years after transplant.

Transplant teams usually check carefully for disease outside the liver before listing a person, because spread elsewhere lowers the benefit. A small amount of stable lung disease does not always rule out a transplant, but this is decided case by case. After transplant, people take anti-rejection medicines for life; some centres choose sirolimus-based anti-rejection treatment because it may also slow EHE.

EHE in children and young people

EHE is very rare in children. When it does occur, it may involve the liver, lungs or soft tissue and can behave more aggressively, with fluid around the lungs in some cases. Children are treated in paediatric sarcoma centres, often using the same principles as in adults: surveillance for stable disease and surgery, sirolimus or chemotherapy for progressive disease.

8. Outlook (prognosis)

The outlook for EHE is very variable. Many people live for many years, even with disease in several organs. A smaller group has aggressive disease that progresses quickly.

Factor Effect on outlook
Disease in one place, fully removed Usually good
Stable multifocal disease without symptoms Often good for years
Pleural or pericardial effusion Poorer outlook (Lau et al., 2011)
Lymph node spread Poorer outlook
Symptoms such as pain, weight loss or anaemia Poorer outlook
Larger tumours with more dividing cells Poorer outlook (Rosenbaum et al., 2020)

Doctors use these factors to decide when treatment is needed and how often scans should be done.

9. Follow-up

Situation Follow-up
After surgery Scans every 3-6 months at first, then less often
Active surveillance Scans every 3-6 months, adjusted to how stable the disease is
On sirolimus Regular scans and blood tests for side effects

10. Living with EHE

  • Find a sarcoma specialist with experience of EHE
  • Connect with patient groups, such as the EHE Rare Cancer Charity and the EHE Foundation
  • Keep a symptom diary, noting pain, breathlessness and tiredness
  • Ask about clinical trials and registries
  • Stay active as much as possible
  • Ask for psychological support, as living with an uncertain, slow-moving cancer can be stressful

11. Frequently asked questions

Question Answer
Is EHE a cancer? Yes. It is a rare sarcoma, although it often grows slowly
Do I need treatment straight away? Not always. Stable disease without symptoms is often watched with scans
Is EHE inherited? No
Can EHE be cured? It can be cured when it is in one place and fully removed; in other cases it can often be controlled for years
Why is it in my liver and lungs at the same time? EHE often appears in several places at diagnosis
Can children get EHE? Yes, but rarely
Will I need lifelong scans? Usually yes, because EHE can change slowly over many years; scans become less frequent when the disease is stable
Can I have children after EHE treatment? Many people can; discuss timing and any medicines, such as sirolimus, with your team before trying for a baby

Research and the future

Because the fusion genes that drive EHE are known, researchers are developing drugs that target the TAZ-CAMTA1 and YAP1-TFE3 signalling pathways. International registries and patient-led research networks have helped to gather data on this rare cancer, and patients are encouraged to take part in them.

12. Questions to ask your care team

  • Where exactly is my EHE, and how many lesions are there?
  • Which fusion gene does my tumour have?
  • Is active surveillance suitable for me?
  • Could surgery or a liver transplant be an option?
  • When would you recommend starting sirolimus or another drug?
  • What signs should make me contact you sooner?
  • Are there clinical trials or registries I can join?

Resources

  1. Antonescu, C.R. et al. (2013) ‘Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma’, Genes, Chromosomes and Cancer, 52(8), pp. 775-784.
  2. Errani, C. et al. (2011) ‘A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites’, Genes, Chromosomes and Cancer, 50(8), pp. 644-653.
  3. Lau, K. et al. (2011) ‘Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer’, Chest, 140(5), pp. 1312-1318.
  4. Mehrabi, A. et al. (2006) ‘Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy’, Cancer, 107(9), pp. 2108-2121.
  5. Rosenbaum, E. et al. (2020) ‘Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets’, Modern Pathology, 33(4), pp. 591-602.
  6. Sardaro, A. et al. (2014) ‘Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor’, Oncology Reviews, 8(2), p. 259.
  7. Sbaraglia, M., Bellan, E. and Dei Tos, A.P. (2021) ‘The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives’, Pathologica, 113(2), pp. 70-84.
  8. Stacchiotti, S. et al. (2021) ‘Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts’, ESMO Open, 6(3), 100170.
  9. Stacchiotti, S. et al. (2023) ‘New molecular insights, and the role of systemic therapies and collaboration for treatment of epithelioid hemangioendothelioma (EHE)’, Current Treatment Options in Oncology, 24(6), pp. 667-679.
  10. National Cancer Institute (2026) Epithelioid Hemangioendothelioma. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-vascular-tumors/epithelioid-hemangioendothelioma (Accessed: October 2026).

Prepared by the editorial team, October 2026.